נוקספיל תרחיף
merck sharp & dohme (israel - 1996) company ltd, israel - posaconazole - תרחיף - posaconazole 40 mg/ml - posaconazole - posaconazole - noxafil is indicated for use in the treatment of the following fungal infections in adults : - invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products - fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b - chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole - coccidioidomycosis in patients with disease that is refractory to amphotericin b itraconazole or fluconazole or in patients who are intolerant of these medicinal products - oropharyngeal candidiasis : as first - line therapy in patients who have severe disease or are immunocompromised in whom response to topical therapy is expected to be poor. refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective anti
נוקספיל תרחיף
merck sharp & dohme israel ltd - posaconazole - תרחיף - posaconazole 40 mg/ml - posaconazole - posaconazole - noxafil is indicated for use in the treatment of the following fungal infections in adults : - invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products - fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b - chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole - coccidioidomycosis in patients with disease that is refractory to amphotericin b itraconazole or fluconazole or in patients who are intolerant of these medicinal products - oropharyngeal candidiasis : as first - line therapy in patients who have severe disease or are immunocompromised in whom response to topical therapy is expected to be poor. refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective anti
נוקספיל 100 מג טבליות עמידות בקיבה
merck sharp & dohme (israel - 1996) company ltd, israel - posaconazole - posaconazole 100 mg - posaconazole
פוסקונזול 100 מג אופק פארמה
ofek pharma ltd, israel - posaconazole - טבליות שחרור מושהה - posaconazole 100 mg - posaconazole
נוקספיל 300 מג תמיסה מרוכזת להכנת תמיסה לעירוי
merck sharp & dohme israel ltd - posaconazole - תרכיז להכנת תמיסה לאינפוזיה - posaconazole 300 mg/vial - posaconazole
פוסאקונאזול אינובמד
inovamed ltd - posaconazole - טבליות שחרור מושהה - posaconazole 100 mg - posaconazole
פוזאטקס וטרינרי
intervet ( israel) ltd - mometasone furoate (as monohydrate); orbifloxacin; posaconazole - orbifloxacin 8.5 mg/ml; mometasone furoate (as monohydrate) 0.9 mg/ml; posaconazole 0.9 mg/ml
אפיקסבן טבע 2.5 מג
teva israel ltd - apixaban - טבליות מצופות פילם - apixaban 2.5 mg - apixaban
אפיקסבן טבע 5 מג
teva israel ltd - apixaban - טבליות מצופות פילם - apixaban 5 mg - apixaban
טייקרב
novartis israel ltd - lapatinib as ditosylate monohydrate - טבליות מצופות פילם - lapatinib as ditosylate monohydrate 250 mg - protein kinase inhibitors - tykerb is indicated for the treatment of adult patients with breast cancer, whose tumours overexpress her2 (erbb2);• in combination with capecitabine for patients with advanced or metastatic disease with progression following prior therapy, which must have included anthracyclines and taxanes and therapy with trastuzumab in the metastatic setting (see section 5.1).• tykerb is indicated in combination with letrozole for the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer that overexpresses the her2 receptor for whom hormonal therapy is indicated. tykerb in combination with an aromatase inhibitor has not been compared to a trastuzumab-containing chemotherapy regimen for the treatment of metastatic breast cancer.